002755 Beijing Aosaikang Pharmaceutical
- 12.96
- -0.39-2.92%
Beijing Aosaikang Pharmaceutical News
Osecon (002755): The painful period of transformation has passed, and the innovation pipeline is gradually gaining strength
Osecon (002755): Early-stage players have BIC potential as profit increased month-on-month
Osecon (002755): Innovation and transformation have given rise to new life for established pharmaceutical companies
Osecon (002755): The light boat has passed Wanzhongshan and set sail for innovative medicine
Osecon (002755): The impact of existing business has bottomed out, and the innovation pipeline is progressing smoothly in clinical practice
Osecon (002755): Reversing losses year over year in the first half of the year, combining simulation and development
Osecon (002755): Steady increase in sales
Osecon (002755) First Coverage Report: Gathering shortages are gradually bottoming out, and innovation and transformation are about to usher in gains
Osecon (002755): Waiting for breakthroughs in innovation-driven transformation
Osecon (002755): The impact of generic drug collection has bottomed out, and the innovative drug pipeline will enter the harvest period
Osecon (002755): The acquisition of Weidecang Incident Landing Pharmaceutical Devices Collaborates to Enhance Competitiveness in the Digestive Field
Osecon (002755) incident review: Maltol iron capsules with excellent Q1 performance were successfully approved and clinical marketing is expected quickly
Osecon (002755): A series of surprises after collaborating with Pharmaceutical Mingkang New Drug to land an innovative drug pipeline
Osecon (002755) Incident Review: 2020 Performance Slightly Exceeds Expectations Subsidiary Patent Authorization Model Highlights Value of Innovative Platforms
Comment on the Osaikang (002755) event: the second domestic anti-tumor drug temozolomide for injection was approved by PPI leader to expand its multi-product line for accelerated growth.
Osecon (002755) In-depth Report: PPI's Leading Multi-Product Line Expansion Enters Accelerated Growth, New First-tier Pharmaceutical Group Innovation Force Rises
Osaikang (002755): significant recovery of results in the third quarter, R & D and steady progress in the future
Osaikang (002755): affected by the epidemic in the first half of the year, the performance declined compared with the same period last year, Q2 improved and was optimistic about the company's long-term development.
Osaikang (002755): high-end first imitation + innovative drugs blossom on domestic PPI leading stars shine
Oriental New Star (002755): the performance inflection point has come to actively seek business transformation.
No Data